Molecular Partners reported Q3 2026 results highlighting a strategic shift to radiopharmaceuticals, driven by encouraging Phase 1/2a data from its lead candidate MP0712 for small cell lung cancer. The company is streamlining operations, planning to cut up to 44% of its workforce to focus resources on advancing Radio-DARPin therapies. MP0712's safety data will be presented in December 2026, with efficacy results expected in 2027. With CHF 57.5 million cash on hand, Molecular Partners aims to fund operations into late 2027 while expanding its radiotherapeutic pipeline targeting various cancers.
Molecular Partners' Q3 2026 financial results and strategic focus on targeted radiotherapy provide context for health sector trading. For readers following health stocks, here is Pluang's market snapshot as of Oct 29, 2026 12:51 WIB: out of 150 priced health-sector US stocks, 104 rose and 43 fell today. Notable movers include TDOC at USD 7.29 with a 1-day change of +5.96%, GSK at USD 48.48 with a 1-day change of -4.83% and 100% buy order activity on Pluang, and BKD at USD 9.99 with a 1-day change of +4.83%.
TGS ASA announced that its shares will be traded ex-dividend at NOK 1.45 per share starting October 29, 2026. This means investors buying the stock from this date will not receive the upcoming dividend payment. The dividend distribution follows appro...
DNO ASA, a Norwegian oil and gas company, announced a cash dividend of NOK 0.375 per share to be paid around November 17, 2026. Shareholders registered by November 9, 2026, will receive the dividend, with shares trading ex-dividend starting November ...
The global music market is projected to grow from $36.13 billion in 2026 to $57.74 billion by 2032, at a CAGR of 8.07%, fueled by paid streaming subscriptions, smartphone adoption, and digital music discovery. North America remains the largest market...
STMicroelectronics reported a 17.9% year-over-year increase in Q3 2026 net revenues to $3.76 billion and net income of $291 million, driven by growth in consumer electronics and personal electronics segments. Gross margin improved to 37.3%, and opera...
Addex Therapeutics has issued 93 million new registered shares, increasing its issued share capital to CHF 3,116,544.96 with 311,654,496 shares at a nominal value of CHF 0.01 each. These shares were fully subscribed by its wholly-owned subsidiary, Ad...
